This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Best Income Stocks to Buy for December 5th
by Zacks Equity Research
UL, SMMF and TM made it to the Zacks Rank #1 (Strong Buy) income stocks list on December 5, 2023.
Down -5.3% in 4 Weeks, Here's Why Unilever PLC (UL) Looks Ripe for a Turnaround
by Zacks Equity Research
Unilever PLC (UL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
6 ETF Areas & Stocks to Win on Upbeat August Retail Sales
by Sanghamitra Saha
Retail sales in the United States grew 0.6% sequentially in August 2023, beating forecasts of a 0.2% advance.
ETF Areas & Stocks to Win on Upbeat July Retail Sales
by Sanghamitra Saha
Retail sales in the United States gained 0.7% sequentially in July of 2023, marking a fourth successive rise.
Zacks Industry Outlook Highlights Unilever, Church & Dwight, Procter & Gamble and Colgate-Palmolive
by Zacks Equity Research
Unilever, Church & Dwight, Procter & Gamble and Colgate-Palmolive have been highlighted in this Industry Outlook article.
4 Soaps & Cleaning Materials Stocks to Gain as Industry Catches On
by Avisekh Bhattacharjee
The soap and cleaning materials industry benefits from revived demand trends, pricing actions, innovation, digital transformation and brand building. Players like UL, CHD, PG and CL look well-poised.
Are Consumer Staples Stocks Lagging McCormick & Company (MKC) This Year?
by Zacks Equity Research
Here is how McCormick (MKC) and Unilever PLC (UL) have performed compared to their sector so far this year.
4 Sector ETFs & Stocks to Win on March Retail Sales
by Sanghamitra Saha
In March 2023, U.S. retail sales experienced a 1% sequential decline, better than market expectations of a 0.4% decrease.
GSK Receives Regulatory Nod for Consumer Healthcare Demerger
by Zacks Equity Research
GSK progresses with the separation of its Consumer Healthcare business from biopharmaceuticals into a separate public company, Haleon, as it gets regulatory approval from the FCA.
Glaxo (GSK) to Buy Sierra for $1.9B, Add Hematology Drug
by Zacks Equity Research
The acquisition of Sierra Oncology (SRRA) will add late-stage oncology pipeline candidate, momelotinib to Glaxo's (GSK) hematology pipeline.
Market Futures Higher Ahead of Opening
by Zacks Equity Research
Market Futures Higher Ahead of Opening
Markets Stampede into the Green; CVS, GSK Beat, YUM Mixed
by Mark Vickery
Seeing our economy gaining in growth is a good reason for investors to become a little less risk-averse.
Glaxo (GSK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Glaxo's (GSK) COVID-19 solutions, newer respiratory and HIV drugs are likely to have driven fourth-quarter sales. The performance of vaccines during Q4 remains to be seen.
Glaxo's (GSK) New Drugs Drive Sales Amid Rising Competition
by Zacks Equity Research
Glaxo (GSK) has made significant progress in its pipeline. Several new drug/line extension approvals are expected in 2022, which should boost the top line in the long term.
Glaxo (GSK) Stock Down As Unilever Decides Not to Raise Offer
by Zacks Equity Research
Unilever decides that it will not raise its offer of $68 billion for Glaxo's (GSK) Consumer Healthcare business.
Glaxo (GSK) Rejects Unilever's $68B Bid for Consumer Business
by Zacks Equity Research
Glaxo (GSK) rejects an offer from Unilever to acquire its consumer business worth 50 billion pounds ($68 billion). However, Unilever is likely to pursue the acquisition of the business.
Shell (RDS.A) Shareholders Overwhelmingly Agree on UK Shift
by Zacks Equity Research
Shareholders in Royal Dutch Shell (RDS.A) have approved the multinational's plan to end its dual-headed structure in favor of a single London-based entity.
Shell (RDS.A) to No Longer be a Dutch Company: Here's Why
by Zacks Equity Research
For investors, the overhaul is seen as a positive move as it simplifies Royal Dutch Shell's (RDS.A) structure and offers greater strategic flexibility.
New Strong Sell Stocks for October 26th
by Zacks Equity Research
BJRI, CARA, BOOM, STNG, and UL have been added to the Zacks Rank #5 (Strong Sell) List on October 26, 2021.
Enbridge (ENB) Partners With Vanguard to Supply RNG in U.S.
by Zacks Equity Research
Enbridge is set to buy more than 2 bcf of RNG per annum from Vanguard's eight anaerobic digesters.
Zacks Industry Outlook Highlights: Procter & Gamble, Unilever, Church & Dwight, Colgate-Palmolive and Clorox Co
by Zacks Equity Research
Zacks Industry Outlook Highlights: Procter & Gamble, Unilever, Church & Dwight, Colgate-Palmolive and Clorox Co
3 Soaps & Cleaning Materials Stocks to Wash Away Industry Blues
by Vidya Nair
Moderation in demand and rise in input costs are headwinds for several soap and cleaning materials companies. Nonetheless, efforts to boost offerings are aiding players like Procter & Gamble (PG), Unilever (UL) and Church & Dwight (CHD).
SAP SE (SAP) Q1 Earnings Improve on a Year-Over-Year Basis
by Zacks Equity Research
SAP SE (SAP) announces upbeat first-quarter 2021 results driven by strength in cloud business.
3 Soaps & Cleaning Stocks That are Braving Industry Challenges
by Vidya Nair
Pandemic-led rise in input costs are a headwind for several soap and cleaning materials companies. Nonetheless, strong demand for personal care items is a boon for players like Procter & Gamble (PG), Unilever (UL) and Church & Dwight (CHD).
Moving Average Crossover Alert: Unilever
by Zacks Equity Research
Unilever (UL) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.